Walleye Capital
IMUX icon

Walleye Capital’s Immunic IMUX Stock Holding History

Walleye Capital’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$6K Buy
+53
New +$138K ﹤0.01% 308

Other funds holding IMUX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Walleye Capital's IMUX Position: Q4 2022 in Review

Walleye Capital sold out of Immunic (IMUX) in Q4 2022, closing a stake of 10,415 shares — an estimated $329K sold.

Walleye Capital first reported a position in IMUX in Q3 2018 and held it in 3 quarters. The position peaked at $329K in Q3 2022. 58 funds tracked by Wall St. Rank hold IMUX as of Q4 2022.

  • Walleye Capital reported no remaining Immunic position as of Q4 2022 after selling out during the quarter.
  • Walleye Capital sold 10,415 Immunic shares in Q4 2022, an estimated $329K.
  • Walleye Capital first reported a position in Immunic in Q3 2018 and held it in 3 quarters.
  • Walleye Capital's Immunic position peaked at $329K in Q3 2022.
  • 58 funds tracked by Wall St. Rank held Immunic as of Q4 2022.

Based on Walleye Capital's 13F filing for Q4 2022, filed 14 Feb 2023.